


Figure 1. CAR-T Products and the Indications They Are Approved for

PHACILITATE	Kymriah	Yescarta	Carveya	Breyanzi	Tecartus	Abecma	Carvykti
Diffuse Large B-Cell Lymphoma	✓	✓	✓	✓			
Follicular Lymphoma		✓		✓			
Relapsed Multiple Myeloma						✓	✓
Refractory Multiple Myeloma						✓	✓
Primary Mediastinal B-Cell Lymphoma		✓		✓			
B-Cell Acute Lymphocytic Leukaemia	✓				✓		
Non-Hodgkin Lymphoma	✓	✓	✓	✓	✓		
Mantle Cell Lymphoma					✓		

Data taken from Global Data, April 2022

Figure 2. The Number of Developmental CAR-T Clinical Trials Currently Taking Place for Different Hematological Oncological Drug Indications



Source: GlobalData

Figure 3. CAR-T Products Currently in Phase III and Pre-Registration

Drug	Company	Indication	Developmental Stage	Location
Yescarta	Gilead Sciences	B-Cell Non-Hodgkin Lymphoma	Pre-Registration	U.S
		Follicular Lymphoma	Phase III	Global
	Fosun Pharma Kite Biotechnology	Diffuse Large B-Cell Lymphoma	Pre-Registration	China
Kymriah	Novartis	Follicular Lymphoma	Pre-Registration	E.U., U.S
		Follicular Lymphoma	Phase III	Japan
		B-Cell Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia	Phase III	Global
		B-Cell Acute Lymphoblastic Leukemia, Follicular Lymphoma and Diffuse Large B-Cell Lymphoma	Phase III	Global
Tecartus	Gilead Sciences	B-Cell Acute Lymphoblastic Leukemia	Pre-Registration	E.U
Carvykti	Legend Biotech	Relapsed and Refractory Multiple Myeloma	Pre-Registration	E.U., Japan
		Multiple Myeloma	Phase III	Global
		Relapsed and Refractory Multiple Myeloma	Phase III	E.U., Japan, U.S
Abecma	Bristol-Myers Squibb	Relapsed and Refractory Multiple Myeloma	Phase III	Global
Breyanzi	Bristol-Myers Squibb	Diffuse Large B-Cell Lymphoma	Pre-Registration	Canada, Japan, Switzerland
		Follicular Lymphoma	Pre-Registration	Canada, Switzerland
		Diffuses Large B-Cell Lymphoma	Pre-Registration	U.S
		Follicular Lymphoma	Phase III	E.U., Global, Japan, U.S
		Primary Mediastinal B-Cell Lymphoma	Phase III	E.U., Global, U.S
		Diffuse Large B-Cell Lymphoma	Phase III	E.U., Global
Carteyva	JW Therapeutics	Follicular Lymphoma	Pre-Registration	China
N/A	Nanjing Iaso Biotherapeutics	Relapsed and Refractory Multiple Myeloma	Phase III	China
N/A	Bristol-Myers Squibb	Oncology	Phase III	Global
N/A	Shanghai Unicar-Therapy Bio-Medicine	Multiple Myeloma	Phase III	Global